Robust preclinical methods are crucial for evaluation of potential antibody drugs, ensuring that time, money, and effort are spent on the most promising candidates with greatest therapeutic potential. Recent advances in preclinical modeling and multi-parameter analysis have significantly improved the rigor of experimental evaluation of lead antibody candidates. Our products provide more biologically relevant models and enable more comprehensive assessment to accelerate therapeutic antibody development.
WANT TO VIEW A CATALOG OF OUR PRECLINICAL OFFERINGS?
Download our brochure to find tools for your mAb preclinical safety and efficacy studies.
Therapeutic Antibody Preclinical Development
Therapeutic Antibody Preclinical Development
Accelerating Antibody Therapeutics Through Advanced Preclinical Modeling and Predictive Evaluation
Developing safe, effective therapeutic antibodies requires robust preclinical models that are predictive of clinical outcomes. While traditional in vitro and in vivo models are fundamental in early discovery, they often lack the physiological complexity needed to fully assess mAb efficacy and safety. To address this gap, advanced in vitro assays, pharmacokinetic analysis, and specialized in vivo models are integrated to deliver more clinically relevant insights in antibody development.
With exclusive access to patient-derived organoid biobanks and assay development services using HUB Organoid technology, along with our partnership with BioIVT for high-quality immune cell subsets, we offer a uniquely comprehensive suite of preclinical evaluation models. These capabilities allow researchers to study mAb function in human-relevant systems, enabling the evaluation of safety, efficacy, and mechanism of action in models that more closely mirror human physiology.
Our integrated toxicology and pharmacology services further support the advancement of antibody candidates, providing critical data on potential off-target effects and safety profiles. By combining patient-derived models with end-to-end analytics, we help bridge the gap between discovery and clinical translation - reducing attrition rates and accelerating pipelines.
Related Categories
ECACC cultures, primary cells, assay-ready cells, and bioprocessing cell lines.
Human iPSC-derived and patient-derived organoids for advanced cell culture.
High quality sera, growth factors, amino acids, vitamins, and more for cell culture.
Comprehensive mass spectrometry reagents to cover your complete workflow.
Analyze preclinical response with MILLIPLEX® multiplexing biomarker assays.
SMC® high sensitivity technology for sensitivity down to the single molecule.
Related Resources
- Transcriptomics
Comprehensively profile infection, disease, or immune response with MULTI-seq analysis.
- Webinar: Metabolomics
Optimize mass spectrometry metabolomics applications.
- MILLIPLEX® Multiplex Assays for Immunology
Profile more immune biomarkers, faster.
- High-Sensitivity Immunoassays in PK/PD Studies
SMC® ultrasensitive immunoassays for preclinical work.
- High Sensitivity Immunogenicity Assays
See how SMC® technology makes detecting anti-drug antibodies easier.
Related Video
Explore our Products & Services
To continue reading please sign in or create an account.
Don't Have An Account?